NCT04300881View on ClinicalTrials.gov

Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

January 5, 2021

Study Completion Date

January 5, 2021

Conditions
Vitreomacular TractionSubretinal Edema
Interventions
DRUG

Eplerenone

Following intravitreal ocriplasmin therapy

Trial Locations (1)

23502

Wagner Macula & Retina Center, Norfolk

Sponsors

Collaborators (1)

ThromboGenics
All Listed Sponsors
collaborator

ThromboGenics

INDUSTRY

lead

Wagner Macula & Retina Center

OTHER

NCT04300881 - Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists) | Biotech Hunter | Biotech Hunter